Activated oxazaphosphorines are transported predominantly by erythrocytes

Annals of Oncology

Volumn 8, Issue 11, 1997, Pages 1139-1144

  Highley, M S ^a,f   Schrijvers, D ^b   Van Oosterom, A T ^c   Harper, P G ^a   Momerency, G ^b   Van Cauwenberghe, K ^b   Maes, R A A ^d   De Bruijn, E A ^c   Edelstein, M B ^e  

^a GUY S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UTRECHT UNIVERSITY   (Netherlands)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

Biological transport; Blood specimen collection; Erythrocytes; Ifosfamide

Indexed keywords

CYCLOPHOSPHAMIDE; IFOSFAMIDE; ISOPHOSPHORAMIDE MUSTARD; OXAZAPHOSPHORINE DERIVATIVE; OXAZOLIDINE DERIVATIVE;

ARTICLE; CANCER CHEMOTHERAPY; DRUG TRANSPORT; ERYTHROCYTE; GAS CHROMATOGRAPHY; HUMAN; HUMAN CELL; MASS SPECTROMETRY; PRIORITY JOURNAL;

EID: 0030716456     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008261203803     Document Type: Article

References (20)

1. Cox PJ. Cyclophosphamide cystitis - identification of acrolein as the causative agent. Biochem Pharmacol 1979; 28: 2045-9.
2. Küpfer A, Aeschlimann C, Wermuth B, CernyT. Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet 1994; 343: 763-4.
3. Highley MS, De Bruijn EA. Erythrocytes and the transport of drugs and endogenous compounds. Pharm Res 1996; 13: 186-95.
4. Momerency G, Van Cauwenberghe K. Slee PHThJ et al. The determination of Cyclophosphamide and its metabolites in blood plasma as stable trifluoroacetyl derivatives by electron capture chemical ionization gas chromatography/mass spectrometry. Biol Mass Spectrom 1994; 23: 149-58.
5. Momerency G, Van Cauwenberghe K. De Bruijn EA et al. Determination of ifosfamide and seven metabolites in blood plasma, as stable trifluoroacetyl derivatives, by electron capture chemical ionisation GC/MS. J High Res Chromatogr 1994; 17: 655-61.
6. Driessen O, Highley MS, Harper PG et al. Description of an instrument for separation of red cells from plasma and measurement of red cell volume. Clin Biochem 1994; 27: 195-6.
7. Highley MS, Harper PG, Slee PHThJ, De Bruijn EA. Preferential location of circulating activated Cyclophosphamide within the erythrocyte. Int J Cancer 1996; 65: 711-2.
8. Domeyer BE, Sladek NE. Kinetics of Cyclophosphamide biotransformation in vivo. Cancer Res 1980; 40: 174-80.
9. Wagner T, Peter G, Voelcker G, Hohorst H-J. Characterisation and quantitative estimation of activated Cyclophosphamide in blood and urine. Cancer Res 1977; 37: 2592-6.
10. Struck RF, Dykes DJ, Corbett TH et al. Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to Cyclophosphamide. Br J Cancer 1983; 47: 15-26.
11. Sladek NE. Metabolism of oxazaphosphorines. Pharmacol Ther 1988; 37: 301-55.
12. Pardridge WM, Landaw EM. Testosterone transport in brain: Primary role of plasma protein-bound hormone. Am J Physiol 1985; 249: E534-42.
13. Cornford EM, Landon KP. Blood-brain barrier transport of CI-912: Single passage equilibration of erythrocyte-borne drug. Ther Drug Monit 1985; 7: 247-54.
14. Kooyman DL, Byrne GW, McClellan S et al. In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science 1995; 269: 89-92.
15. Jain RK. Transport of molecules in the tumor interstitium: A review. Cancer Res 1987; 47: 3039-51.
16. Denekamp J. Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer 1982; 45: 136-9.
17. Malik GK, Goel GK, Vishwanathan PN et al. Free and erythrocyte-bound bilirubin in neonatal jaundice. Acta Paediatr Scand 1986: 75: 545-9.
18. Hiramatsu R, Nisula BC. Erythrocyte-associated component of blood cortisol. Ann NY Acad Sci 1988; 538: 159-66.
19. Baraona E, Di Padova C, Tabasco J, Lieber CS. Red blood cells: A new major modality for acetaldehyde transport from liver to other tissues. Life Sci 1987; 40: 253-8.
20. Murphy SE, Coletta KA. Two types of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone hemoglobin adducts, from metabolites which migrate into or are formed in red blood cells. Cancer Res 1993; 53: 777-83.